Imunon Q2 2026: $6.9M Cash, Going Concern Warning, and $10M Financing Closed
IMNN sits 16% above its 52-week low of $1.47 on light trading volume (0.3× avg).
Summary
Imunon reports $6.9M in cash, a $7.1M H1 net loss, and a going concern warning. A $10M financing closed in June, but $5M is restricted, and the ATM program continues to dilute shareholders.
Key Events · Earnings and Guidance · IMNN
-
Going Concern Warning Reiterated
Management states substantial doubt about the company's ability to continue as a going concern, with current capital insufficient to fund operations for the next twelve months.
-
Cash Position and Burn
Unrestricted cash of $6.9 million at June 30, 2026, after burning $7.0 million in H1 2026. $5.0 million of the $10 million June financing is restricted as collateral.
-
June 2026 Financing Closed
Closed a $10 million transaction with Streeterville Capital on June 3, 2026, consisting of $2.5 million in Series A preferred stock, a $2.72 million A-1 note, and a $5.0 million B note. $5 million of proceeds are restricted.
-
ATM Dilution Continues
Sold 356,976 shares for net proceeds of $842,702 in H1 2026. Post-quarter, sold another 162,804 shares for $298,494. The ATM program has $12.2 million remaining capacity.
Analysis · IMNN · Life Sciences
With only $6.9 million in unrestricted cash after burning $7.0 million in the first half, Imunon ended Q2 2026 on a precarious footing. Management reiterates substantial doubt about the company's ability to continue as a going concern, stating current capital is insufficient to fund operations for the next twelve months. A $10 million financing closed in June — a mix of preferred stock and secured notes — provides a lifeline, but $5 million of the proceeds is restricted as collateral, leaving just $5 million immediately available. The company continues to sell shares through its ATM program, raising an additional $298,494 after the quarter. While clinical progress with IMNN-001 in ovarian cancer is encouraging, the financial runway remains critically short, and further dilution is virtually certain.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.2% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.80%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMNN was trading at $1.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $1.47 to $7.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.